Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
Sponsor: ETH Zurich
Summary
With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed/refractory AML.
Official title: Pharmacoscopy-guided Clinical Standard-of-care in Relapsed/Refractory Acute Myeloid Leukemia, a Randomized Phase-2 Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
88
Start Date
2024-09-02
Completion Date
2026-06-30
Last Updated
2025-05-16
Healthy Volunteers
No
Conditions
Interventions
Pharmacoscopy
Pharmacoscopy (PCY) is an image-based ex vivo drug testing platform developed by the Snijder lab at the ETH Zurich. PCY measures in the drug response of patient cells from small biopsies using automated microscopy and single-cell image analysis. PCY prioritizes treatments based on their specific efficacy against AML cells, while minimizing toxicity to healthy (non-malignant) cells in the patient biopsy.
Clinical standard-of-care (physician's choice)
Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
Locations (2)
Inselspital Bern
Bern, Canton of Bern, Switzerland
University Hospital Zurich
Zurich, Canton of Zurich, Switzerland